Cyclo Therapeutics Appoints Russ Belden as Acting Chief Commercial Officer

Preeminent biotechnology commercialization leader with over 33 years of industry experience, including 16 years at Genentech with a pivotal role in commercializing products across multiple therapeutic areas

March 10, 2021 08:35 AM Eastern Standard Time

GAINESVILLE, Fla.–(BUSINESS WIRE)–Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families suffering from disease, today announced the appointment of Russ Belden as Acting Chief Commercial Officer.